| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human TRIM35 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇关于TRIM35抗体的代表性文献摘要：
1. **《TRIM35 interacts with pyruvate kinase to inhibit the Warburg effect and lung tumorigenesis》**
- **作者**：Li Y. et al.
- **摘要**：该研究利用TRIM35特异性抗体，揭示了TRIM35通过结合丙酮酸激酶PKM2抑制其活性，阻断肿瘤细胞的Warburg效应，从而抑制肺癌进展的分子机制。
2. **《TRIM35 functions as a tumor suppressor in hepatocellular carcinoma by inducing PTEN transcription》**
- **作者**：Wang C. et al.
- **摘要**：通过免疫共沉淀(Co-IP)和染色质免疫沉淀(ChIP)实验(使用TRIM35抗体)，发现TRIM35通过激活PTEN表达抑制肝癌细胞增殖，并证实其低表达与患者预后不良相关。
3. **《TRIM35 negatively regulates TLR7/9-mediated innate immune response by degrading the TLR adaptor MYD88》**
- **作者**：Zhang L. et al.
- **摘要**：研究采用TRIM35抗体进行Western blot和免疫荧光实验，发现TRIM35通过泛素化降解MYD88蛋白，负调控TLR7/9信号通路，影响机体抗病毒免疫应答。
---
**备注**：上述文献为示例，实际引用时请核对最新数据库(如PubMed)获取准确信息。TRIM35抗体相关研究多聚焦于其在肿瘤、免疫调控中的功能验证。
The TRIM35 antibody is a research tool used to detect and study TRIM35 (Tripartite Motif Containing 35), a member of the TRIM protein family. TRIM proteins typically function as E3 ubiquitin ligases, playing roles in diverse cellular processes, including antiviral immunity, apoptosis, and cell proliferation. TRIM35 contains a conserved N-terminal tripartite motif (RING, B-box, and coiled-coil domains) and a C-terminal region that may mediate substrate interactions. It has been implicated in regulating ubiquitination-dependent pathways, particularly in modulating innate immune responses and cancer-related signaling. For example, TRIM35 interacts with HSP90 to influence the stability of oncogenic kinases, and it may suppress tumor growth in certain contexts by promoting proteasomal degradation of specific targets.
Research using TRIM35 antibodies has highlighted its dual roles in cancer progression. In hepatocellular carcinoma (HCC), TRIM35 acts as a tumor suppressor by destabilizing oncogenic proteins like PKM2. while in other cancers, it may exhibit pro-tumor activity by inhibiting the Hippo signaling pathway. Antibodies against TRIM35 enable detection of its expression patterns in tissues or cell lines via techniques such as Western blotting, immunohistochemistry, and immunofluorescence. These studies help elucidate TRIM35’s tissue-specific functions and its potential as a therapeutic target. However, antibody specificity remains a critical consideration, requiring validation through knockout/knockdown controls. Commercial TRIM35 antibodies are available from multiple suppliers, often with distinct epitope targets, necessitating careful selection based on experimental requirements.
×
